Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia

Table 4 Multivariate regression: SP ^a -IPTp ^b doses (categorical variables) associated with outcomes of interest

Adjusted model ^c	<2 vs ≥2 doses PR ^d (95% CI ^e )	<3 vs ≥ 3 doses PR (95% CI)	2 vs ≥3 doses PR (95% CI)
Placental infection^f
Paucigravid	0.77 (0.58- 1.01)	0.89 (0.64-1.23)	1.06 (0.71-1.57)
Multigravid	1.00 (0.66-1.52)	0.87 (0.55-1.39)	0.83 (0.49-1.39)
Low birth weight (<2,500 g)
Paucigravid	0.33 (0.12-0.91)	0.43 (0.10-1.81)	Could not compute
Multigravid	0.51 (0.21-1.25)	0.26 (0.06-1.11)	Could not compute
Preterm (<37 weeks)
Paucigravid	0.93 (0.49-1.78)	0.70 (0.34-1.44)	Could not compute
Multigravid	0.28 (0.13-0.60)	0.15 (0.04-0.55)	Could not compute
Composite birth outcome^g
Paucigravid	1.09 (0.73-1.61)	0.84 (0.54-1.31)	Could not compute
Multigravid	0.50 (0.32-0.78)	0.43 (0.24-0.80)	Could not compute
Any infection^h
Paucigravid	0.76 (0.58-0.99)	0.88 (0.65-1.21)	1.06 (0.72-1.55)
Multigravid	1.04 (0.69-1.58)	0.86 (0.54-1.36)	0.79 (0.48-1.33)

^aSP = sulphadoxine pyrimethamine.
^bIPTp = intermittent preventive treatment for malaria in pregnancy.
^c Model adjusted for: Age group (<18, 18–35, >35), gravidity as an interaction term, sleeping under an ITN the last night at home, living in a home treated with IRS, urban, facility, delivered during the wet season, marital status.
^dPR = prevalence ratio.
^eCI = 95% confidence interval.
^fPlacental infection outcome: histopathology classes 1–4 vs class 5.
^gComposite birth outcome defined as infants born with any of: LBW, SGA or preterm.
^hAny infection defined as: pathology classes 1–4, blood smear positive (maternal, placental or cord blood).

ISSN: 1475-2875